Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.65 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.62 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469007 | 0.92 | BCHE (0.67) | BCHESPHK2SPHK1FFAR1FFAR4 | |
| SCHEMBL7391510 | 0.86 | SPHK2 (0.82) | BCHESPHK2SPHK1PARP10 | |
| SCHEMBL4344215 | 0.85 | TAAR1 (0.54) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL965290 | 0.85 | MAOB (0.62) | PARP10 | |
| SCHEMBL69355 | 0.85 | MAOB (0.60) | BCHESPHK2SPHK1 | |
| SCHEMBL2295843 | 0.83 | BCHE (0.61) | BCHEFFAR1FFAR4MEN1KMT2A | |
| SCHEMBL963902 | 0.83 | SCN3A (0.78) | MEN1KMT2APARP10 | |
| SCHEMBL87713 | 0.83 | MAOB (0.59) | BCHEMEN1KMT2ACYP2D6 | |
| SCHEMBL6926688 | 0.83 | FFAR1 (0.64) | BCHESPHK2SPHK1FFAR1FFAR4 | |
| SCHEMBL69319 | 0.82 | TAAR1 (0.52) | SPHK2SPHK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963280-B1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2015-10-28 | — | — | EP | disclosed |
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| EP-1963280-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1E, CACNA1I | BCHE 3957/4885SPHK2 599/4885SPHK1 831/4885 |
| US-20110046129-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1I, KCNN2 | BCHE 2604/4885SPHK2 525/4885SPHK1 756/4885 |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | CACNA1A, CACNA1I, KCNN2 | BCHE 2604/4885SPHK2 525/4885SPHK1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.